Update on Rotarix™: An oral human rotavirus vaccine
Artículo

Open/ Download
Publication date
2009Metadata
Show full item record
Cómo citar
O'Ryan Gallardo, Miguel
Cómo citar
Update on Rotarix™: An oral human rotavirus vaccine
Abstract
Worldwide, rotaviruses are the single most important agents of severe gastroenteritis in infants and young children. Globally, it is estimated that every year rotavirus gastroenteritis causes more than 125 million episodes of diarrhea and nearly 527,000 deaths, mainly in developing countries. The development of new effective and safe rotavirus vaccines was recognized as the most effective intervention strategy that could yield a significant impact on the burden of rotavirus disease. Rotarix™ is an oral live-attenuated human rotavirus vaccine containing a single G1P[8] strain. The first oral dose may be administered as early as 6 weeks of age, with a minimum interval of 4 weeks prior to second dose; the vaccination course should be completed by the age of 24 weeks according to the manufacturer. In the USA, the upper age limit for the second dose has recently been recommended at 32 weeks of age by the Advisory Committee on Immunization Practices. The development program for Rotarix inclu
Indexation
Artículo de publicación SCOPUS
Identifier
URI: https://repositorio.uchile.cl/handle/2250/164918
DOI: 10.1586/erv.09.136
ISSN: 14760584
17448395
Quote Item
Expert Review of Vaccines, Volumen 8, Issue 12, 2018, Pages 1627-1641
Collections